CytoDyn reports positive survival data for patients with advanced colorectal cancer

e previously treated CRC patients are confirmed prospectively, the Company believes leronlimab could be used effectively to treat a wide range of solid tumor types. In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting. The data driving this working theory has shown particular promise in the treatment of patients with advanced metastatic triple-negative breast cancer (“mTNBC”).

The upcoming presentation at the ESMO Gastrointestinal Cancers Congress by Dr. Weinberg will highlight the data and evidence supporting the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology. Dr. Jacob Lalezari, CEO of CytoDyn, expressed enthusiasm for the ongoing Phase II trial in patients with mCRC, designed to confirm these observations and garner clinical confirmation of the Company’s working theory. Enrolling additional patients is a key focus as they work towards validating the positive outcomes.

CytoDyn is a clinical-stage biotechnology company dedicated to advancing the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody designed to bind to C-C chemokine receptor type 5 (CCR5). This protein is present on the surface of specific immune system cells and is believed to play a role in various disease processes. Leronlimab has been studied across different therapeutic areas, including oncology, infectious disease, and autoimmune conditions, showcasing its potential for wide-ranging impact.

It is important to note that this news release contains forward-looking statements regarding clinical trial outcomes, product progression, market positioning, future performance, and business strategy. It is advisable not to solely rely on these statements, as they are based on current expectations and may be subject to change based on unforeseen events or circumstances. Detailed information about these statements, our Company, and potential risk factors can be found in our Annual Report on Form 10-K for the fiscal year ending May 31, 2024, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. commits to updating any forward-looking statements as needed based on new information or future developments.

For further media inquiries, please contact CytoDyn via email.